Malaria in Pregnancy: Nutrition and Immunologic Effects (MAL2)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Malaria accounts for a major proportion of the disease burden in Tanzania with 14 to 18 million new malaria cases being reported each year resulting in 100,000-125,000 deaths. Malaria results in impaired productivity for those between 15-55 years and lost learning opportunities in the 5-25 year age group. Dar es Salaam is characterized as an area with endemic and perennial malaria, with transmission occurring during the entire year. P. falciparum accounts for more than 95% of malaria infections. A number of interventions have contributed to reducing the burden of the disease in some settings in Tanzania and beyond, including vector control measures, bed nets, and prophylaxis and treatment of malaria. However, malaria remains a serious problem among pregnant women and children. We will examine the efficacy of micronutrient supplements as a means of enhancing immune response to malaria in pregnancy and reducing the risks of associated adverse clinical outcomes. If successful, such a low-cost intervention would be added to the armamentarium against this disease.
NOTE: The time frames listed for the maternal malaria and hemoglobin outcomes were updated on 4/22/15. This record initially indicated that maternal malaria anemia and hemoglobin would be measured at several specific time points throughout the study. Instead, maternal malaria was measured throughout pregnancy and hemoglobin was measured only at delivery. Due to an oversight, we did not update this record when this protocol change took effect at the start of the study.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Dar es Salaam, Tanzania, PO BOX 65001
- Muhimbili University of Health and Allied Sciences
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Primigravida or secundigravidae
- At or before 13 weeks of gestation
- HIV-negative
- Intend to stay in Dar es Salaam until delivery and for at least 6 weeks thereafter
Exclusion Criteria:
- Not primigravida or secundigravidae
- After 13 weeks of gestation
- HIV-positive
- Do not intend to stay in Dar es Salaam until delivery and for at least 6 weeks thereafter
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Faktoriel opgave
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Daglig oral dosis fra indskrivning til fødsel
|
|
Aktiv komparator: Vitamin A
|
Daily oral dose of 2500 IU from enrollment until delivery
|
|
Aktiv komparator: Zinc
|
Daily oral dose of 25 mg from enrollment until delivery
|
|
Aktiv komparator: Vitamin A + Zinc
|
Daily oral dose of 2500 IU from enrollment until delivery
Daily oral dose of 25 mg from enrollment until delivery
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Forekomst af placenta malaria
Tidsramme: Levering
|
Placental infektionsstatus vil blive kategoriseret som inficeret, hvis der er aseksuelle parasitter i placentablodet; ikke inficeret, hvis placentablodudstrygningen er negativ; eller status ukendt, hvis ingen placenta udstrygning er tilgængelig.
|
Levering
|
|
Lav fødselsvægt
Tidsramme: Levering
|
Lav fødselsvægt vil blive defineret som fødselsvægt under 2500 gram.
|
Levering
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maternal anemia
Tidsramme: Delivery
|
Anemia is defined as hemoglobin less than 11 g/dl.
Severe anemia is less than 8.5 g/dl.
|
Delivery
|
|
Perinatal death
Tidsramme: at or after 28 weeks of gestation and in the first 7 days of life
|
at or after 28 weeks of gestation and in the first 7 days of life
|
|
|
Maternal malaria
Tidsramme: During pregnancy
|
Maternal malaria will be defined as fever within the last 72 hours with any parasitemia on a peripheral blood smear.
|
During pregnancy
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Ferdinand Mugusi, MD, MMed, Muhimbili University of Health and Allied Sciences
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- HD57941-01A2
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .